{"disease":{"id":"heart-failure","name":"Heart Failure","therapeutic_area":"Cardiovascular","data":{"aiSummary":"The treatment landscape for heart failure has evolved significantly with the introduction of SGLT2 inhibitors and ARNI. These agents, along with beta-blockers and MRAs, form the cornerstone of guideline-directed medical therapy (GDMT) for HFrEF. For HFpEF, SGLT2 inhibitors have shown benefit. The pipeline includes novel agents like omecamtiv mecarbil and devices such as Barostim, offering potential for improved outcomes. Future research focuses on personalized approaches and targeting specific pathways to further improve patient outcomes.","drug_count":8,"description":"Heart failure is a chronic, progressive condition in which the heart cannot pump enough blood to meet the body\\","subtype_count":9},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.931Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"empagliflozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jardiance","generic_name":"empagliflozin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":66,"revenue":"6500","mechanism":"SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity."},{"drug_id":"dapagliflozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"tolvaptan","indication_name":"Fluid retention in heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Samsca","generic_name":"TOLVAPTAN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Vasopressin V2 receptor","drug_class":"Vasopressin V2 Receptor Antagonist [EPC]","quality_score":80,"revenue":"1200","mechanism":"Samsca works by blocking the action of vasopressin, a hormone that regulates water levels in the body."},{"drug_id":"valsartan","indication_name":"Chronic heart failure in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":77,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"valsartan","indication_name":"Symptomatic heart failure in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":77,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"valsartan","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":77,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"chembl-chembl1751","indication_name":"Heart Failure in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DIGOXIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cardiac Glycoside [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"ethacrynic-acid","indication_name":"Edema in Congestive Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"olprinone","indication_name":"Acute heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loprinone","generic_name":"OLPRINONE","company_name":"","drug_phase":"marketed","molecular_target":"Phosphodiesterase 3","drug_class":"olprinone","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"diovan","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diovan","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ubidecarenone","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin Q","generic_name":"UBIDECARENONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Methylating Agent [EPC]","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"dapaglifozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chlorothiazide","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"chlorothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"chlorothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"vericiguat","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verquvo","generic_name":"VERICIGUAT","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":52,"revenue":null,"mechanism":"Verquvo works by stimulating the enzyme guanylate cyclase to increase levels of a molecule called cGMP, which helps to relax blood vessels and improve heart function."},{"drug_id":"vericiguat","indication_name":"Heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verquvo","generic_name":"VERICIGUAT","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":52,"revenue":null,"mechanism":"Verquvo works by stimulating the enzyme guanylate cyclase to increase levels of a molecule called cGMP, which helps to relax blood vessels and improve heart function."},{"drug_id":"enalapril-maleate","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"levosimendan","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Simdax","generic_name":"LEVOSIMENDAN","company_name":"","drug_phase":"phase_3","molecular_target":"Troponin C, slow skeletal and cardiac muscles","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":39,"revenue":null,"mechanism":"Simdax works by binding to troponin C, increasing calcium sensitivity in cardiac muscle cells, allowing for improved heart function without increasing oxygen demand."},{"drug_id":"captopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capozide 25/15","generic_name":"CAPTOPRIL","company_name":"Aarxion Anda Hlding","drug_phase":"marketed","molecular_target":"Renin","drug_class":"Thiazide Diuretic [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"quinapril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Accupril","generic_name":"QUINAPRIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"eplerenone","indication_name":"Chronic Heart Failure Following Myocardial Infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inspra","generic_name":"EPLERENONE","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Aldosterone Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Inspra works by blocking the action of aldosterone, a hormone that can cause the body to retain too much salt and water."},{"drug_id":"candesartan-cilexetil","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atacand","generic_name":"CANDESARTAN CILEXETIL","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":62,"revenue":null,"mechanism":"Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function."},{"drug_id":"ivabradine","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlanor","generic_name":"IVABRADINE","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","drug_class":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"aldactone","indication_name":"NYHA Class III-IV heart failure with reduced ejection fraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"non-interventional-study","indication_name":"Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"metoprolol","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"frusemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Frusemide","company_name":"Melbourne Health","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"frusemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Frusemide","company_name":"Melbourne Health","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lisinopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zestril","generic_name":"lisinopril","company_name":"Generic (originally Merck/AstraZeneca)","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"Thiazide Diuretic [EPC]","quality_score":55,"revenue":null,"mechanism":"Inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, lowering blood pressure and reducing cardiac workload."},{"drug_id":"torasemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"torasemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylclothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enduron","generic_name":"methylclothiazide","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"methylclothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enduron","generic_name":"methylclothiazide","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"azosemide","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azosemid","generic_name":"AZOSEMIDE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"azosemide","quality_score":null,"revenue":null,"mechanism":"Azosemide works by inhibiting the reabsorption of sodium and chloride ions in the kidneys."},{"drug_id":"benzylhydrochlorothiazide","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Behyd","generic_name":"benzylhydrochlorothiazide","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Behyd works by blocking sodium reabsorption in the kidneys, which increases urine production and reduces blood pressure."},{"drug_id":"chlortalidone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combipres","generic_name":"Chlortalidone","company_name":"University Hospital Birmingham","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"chlortalidone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combipres","generic_name":"Chlortalidone","company_name":"University Hospital Birmingham","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"enalapril","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"enalapril","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"ACE inhibitor","quality_score":60,"revenue":null,"mechanism":"ACE inhibitor prodrug that is converted to enalaprilat, blocking angiotensin-converting enzyme to lower blood pressure."},{"drug_id":"nesiritide","indication_name":"Decompensated chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Natrecor","generic_name":"NESIRITIDE","company_name":"Scios Llc","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Natriuretic Peptide","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"hydrochlorothiazide","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":59,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"hydrochlorothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":59,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"hydrochlorothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":59,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"spironolactone","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"spironolactone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"spironolactone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"dapa","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"persantin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Persantin","company_name":"Boehringer Ingelheim","drug_phase":"phase_1","molecular_target":"Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"carvedilol","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coreg","generic_name":"CARVEDILOL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":70,"revenue":null,"mechanism":"Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function."},{"drug_id":"fosinopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monopril","generic_name":"FOSINOPRIL","company_name":"","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":64,"revenue":null,"mechanism":"Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"bumetanide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"bumetanide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"milrinone-lactate","indication_name":"Acute decompensated heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Milrinone Lactate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase-3 (PDE-3) enzyme","drug_class":"Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator","quality_score":66,"revenue":null,"mechanism":"Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation."},{"drug_id":"milrinone-lactate","indication_name":"Acute decompensated heart failure in patients receiving digoxin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Milrinone Lactate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase-3 (PDE-3) enzyme","drug_class":"Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator","quality_score":66,"revenue":null,"mechanism":"Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation."},{"drug_id":"milrinone-lactate","indication_name":"Acute decompensated heart failure in patients receiving diuretics","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Milrinone Lactate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase-3 (PDE-3) enzyme","drug_class":"Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator","quality_score":66,"revenue":null,"mechanism":"Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation."},{"drug_id":"enalaprilat","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRILAT","company_name":"Biovail Labs Intl","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"enalaprilat","quality_score":75,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"olmesartan","indication_name":"heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":60,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"nitroprusside","indication_name":"Acute exacerbation of chronic congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"nitroprusside","indication_name":"Acute heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cilexetil","indication_name":"Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Candesartan Cilexetil","generic_name":"CILEXETIL","company_name":"Alembic","drug_phase":"marketed","molecular_target":"Ace Inhibitor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Candesartan cilexetil works by blocking the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function."},{"drug_id":"milrinone-lactate-in-dextrose-5-in-plastic-container","indication_name":"Acute decompensated heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primacor","generic_name":"Milrinone Lactate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Phosphodiesterase 3","drug_class":"Phosphodiesterase 3 Inhibitor","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"dipyridamole","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Persantine","generic_name":"DIPYRIDAMOLE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1."},{"drug_id":"metolazone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaroxolyn","generic_name":"METOLAZONE","company_name":"I3 Pharms","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"metolazone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaroxolyn","generic_name":"METOLAZONE","company_name":"I3 Pharms","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"acetyldigitoxin","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acylanid","generic_name":"ACETYLDIGITOXIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sodium/potassium-transporting ATPase","drug_class":"acetyldigitoxin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"furosemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lasix","generic_name":"furosemide","company_name":"Generic (originally Hoechst AG)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"Loop Diuretic [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"furosemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lasix","generic_name":"furosemide","company_name":"Generic (originally Hoechst AG)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"Loop Diuretic [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"digoxin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lanoxin","generic_name":"digoxin","company_name":"Generic (originally Burroughs Wellcome/GSK)","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2","drug_class":"Cardiac Glycoside [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"torsemide","indication_name":"Edema associated with heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":80,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"ramipril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"chlorthalidone","indication_name":"Edema associated with congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ethacrynic-acid","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ethacrynic-acid","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"forxiga","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"jardiance","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jardiance","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"simdax","indication_name":"Congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simdax","company_name":"Yooyoung Pharmaceutical Co., Ltd.","drug_phase":"phase_3","molecular_target":"ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, Troponin C, slow skeletal and cardiac muscles","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mavik","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mavik","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hctz","indication_name":"heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"fosinopril","indication_name":"Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monopril","generic_name":"FOSINOPRIL","company_name":"","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":64,"revenue":null,"mechanism":"Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"chlorothiazide","indication_name":"Edema in Congestive Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"enalapril-maleate","indication_name":"Symptomatic Congestive Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"acetazolamide","indication_name":"Edema due to congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1751","indication_name":"Heart Failure in Adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DIGOXIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cardiac Glycoside [EPC]","quality_score":20,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"nitroglycerin","indication_name":"Evaluating the effects of nitroglycerin on heart function and urinary output in patients with acute heart failure","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":48,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"torsemide","indication_name":"Heart failure with overactive bladder","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":80,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."}],"offLabel":[],"totalMarketed":94,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06268535","title":"Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study","phase":"","overall_status":"COMPLETED","enrollment_count":36580288,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06255418","title":"Big Data to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure","phase":"","overall_status":"COMPLETED","enrollment_count":7860560,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03694392","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","phase":"","overall_status":"COMPLETED","enrollment_count":2776278,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT05096039","title":"Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models","phase":"","overall_status":"COMPLETED","enrollment_count":1614719,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05329727","title":"The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Wonju Severance Christian Hospital","has_results":false},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03939624","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","phase":"","overall_status":"COMPLETED","enrollment_count":419734,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT07141914","title":"A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":285327,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05848206","title":"Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.","phase":"","overall_status":"COMPLETED","enrollment_count":251831,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT02612688","title":"Pragmatic Trial of Video Education in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":197692,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT05053828","title":"Type 2 Diabetes With Antiplatelet Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":173464,"lead_sponsor_name":"Tabula Rasa HealthCare","has_results":false},{"nct_id":"NCT07150754","title":"Cardiological Drug Classes And Falls in Older Adults","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05961748","title":"Registry of Multicenter Brain-Heart Comorbidity in China","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT03515655","title":"A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)","phase":"","overall_status":"UNKNOWN","enrollment_count":99209,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03733665","title":"HES and NICOR Data Linkage for Cardiac Failure Population Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT06248658","title":"Assessment of the Impact of Clinical Decision Support Systems Included in Electronic Health Records","phase":"","overall_status":"COMPLETED","enrollment_count":66166,"lead_sponsor_name":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","has_results":false},{"nct_id":"NCT03931200","title":"Demographic and Clinical Characteristics, Treatment Patterns and Clinical Outcomes of Heart Failure Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"China Cardiovascular Association","has_results":false},{"nct_id":"NCT03508271","title":"Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure","phase":"","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06914102","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":58387,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT00344513","title":"Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50000,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03099889","title":"WHISH-2-Prevent Heart Failure","phase":"NA","overall_status":"UNKNOWN","enrollment_count":49936,"lead_sponsor_name":"Memorial Hospital of Rhode Island","has_results":false},{"nct_id":"NCT04584645","title":"A Digital Flu Intervention for People With Cardiovascular Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":49138,"lead_sponsor_name":"Evidation Health","has_results":true},{"nct_id":"NCT06671314","title":"Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction","phase":"","overall_status":"COMPLETED","enrollment_count":42494,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT05096143","title":"A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data","phase":"","overall_status":"COMPLETED","enrollment_count":42269,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02795910","title":"Integrated Primary Care for Diabetes and Cardiovascular Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40577,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04237701","title":"Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System","phase":"","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT04743063","title":"Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04648852","title":"The HUNT for Heart Failure\" Risk Score","phase":"","overall_status":"COMPLETED","enrollment_count":36511,"lead_sponsor_name":"Helse Nord-Trøndelag HF","has_results":false},{"nct_id":"NCT03549754","title":"iCaReMe Global Registry","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04684836","title":"Comparative Effectiveness of Telemedicine in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":33100,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07515859","title":"Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography","phase":"","overall_status":"COMPLETED","enrollment_count":31486,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT07493590","title":"CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT07149688","title":"Village-Based Management of Chronic Cardiovascular Disease in Qu Jiang Elderly Population Registry: The BOUQUET Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06459934","title":"Clinical Outcomes of Cardiovascular Disease","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT06914141","title":"Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","phase":"","overall_status":"COMPLETED","enrollment_count":28118,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06980623","title":"Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05748691","title":"Switching From Cardiac Troponin I to T","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT07390110","title":"Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25664,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03078166","title":"Global Congestive Heart Failure Registry","phase":"","overall_status":"COMPLETED","enrollment_count":25000,"lead_sponsor_name":"Hamilton Health Sciences Corporation","has_results":false},{"nct_id":"NCT04844944","title":"The Helios Heart Registry: A Standardized Registry for Patients With Specific Cardiac Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"Helios Health Institute GmbH","has_results":false},{"nct_id":"NCT06099028","title":"Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China","phase":"","overall_status":"COMPLETED","enrollment_count":22500,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06884436","title":"Preoperative Cardiology Consultation and the Incidence of Major Adverse Cardiac Events（MACE）","phase":"","overall_status":"COMPLETED","enrollment_count":22000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06683001","title":"National Heart Failure Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","has_results":false},{"nct_id":"NCT04158479","title":"China Extracorporeal Life Support Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06312501","title":"Remote Patient Monitoring for Patients With Heart Failure in France","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Satelia","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}